Search research articles
Contact Us
Filters
Showing results (21-30 of 221) with videos related to
Page
of 23
Sort By:
Journal of the Endocrine Society
|
May 15, 2026
Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications
Emma Boretti, Jean-Michel Dogné, Jonathan Douxfils
Frontiers in Cardiovascular Medicine
|
July 24, 2023
Editorial: Insights in thrombosis: 2022
Jonathan Douxfils, Hugo Ten Cate, Roberto Pola
Climacteric : the Journal of the International Menopause Society
|
July 9, 2024
Fezolinetant for VMS: a balanced view on efficacy and safety needed
Jonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Clinical Chemistry and Laboratory Medicine
|
April 22, 2022
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Julien Favresse, Jean-Michel Dogné, Jonathan Douxfils
Lancet (London, England)
|
May 18, 2024
Totality of evidence refutes neoplasm risk with fezolinetant - Authors' reply
Jonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
The Journal of Infection
|
August 18, 2021
Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ
Jonathan Douxfils, Constant Gillot, François Mullier, et al.
International Journal of Laboratory Hematology
|
May 10, 2019
An update on laboratory assessment for direct oral anticoagulants (DOACs)
Robert C Gosselin, Dorothy M Adcock, Jonathan Douxfils
Thrombosis Research
|
November 3, 2019
Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation
Saartje Bloemen, Suzanne Zwaveling, François Mullier, et al.
Hamostaseologie
|
July 30, 2020
Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?
Sara Reda, Laure Morimont, Jonathan Douxfils, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 16, 2022
The myths behind DOAC measurement: Analyses of prescribing information from different regulatory bodies and a call for harmonization
Robert C Gosselin, Emmanuel J Favaloro, Jonathan Douxfils
Page
of 23
Search research articles
Search
Showing results (21-30 of 221) with videos related to
Sort By:
Page
of 23
Journal of the Endocrine Society
|
May 15, 2026
Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications
Emma Boretti, Jean-Michel Dogné, Jonathan Douxfils
Frontiers in Cardiovascular Medicine
|
July 24, 2023
Editorial: Insights in thrombosis: 2022
Jonathan Douxfils, Hugo Ten Cate, Roberto Pola
Climacteric : the Journal of the International Menopause Society
|
July 9, 2024
Fezolinetant for VMS: a balanced view on efficacy and safety needed
Jonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Clinical Chemistry and Laboratory Medicine
|
April 22, 2022
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Julien Favresse, Jean-Michel Dogné, Jonathan Douxfils
Lancet (London, England)
|
May 18, 2024
Totality of evidence refutes neoplasm risk with fezolinetant - Authors' reply
Jonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
The Journal of Infection
|
August 18, 2021
Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ
Jonathan Douxfils, Constant Gillot, François Mullier, et al.
International Journal of Laboratory Hematology
|
May 10, 2019
An update on laboratory assessment for direct oral anticoagulants (DOACs)
Robert C Gosselin, Dorothy M Adcock, Jonathan Douxfils
Thrombosis Research
|
November 3, 2019
Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation
Saartje Bloemen, Suzanne Zwaveling, François Mullier, et al.
Hamostaseologie
|
July 30, 2020
Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?
Sara Reda, Laure Morimont, Jonathan Douxfils, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 16, 2022
The myths behind DOAC measurement: Analyses of prescribing information from different regulatory bodies and a call for harmonization
Robert C Gosselin, Emmanuel J Favaloro, Jonathan Douxfils
Page
of 23